- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04733040
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) (NewPLACE)
A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tbilisi, Georgia
- Managadze National Center of Urology
-
Tbilisi, Georgia
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
-
-
-
-
Aachen, Germany
- University Hospital Aachen
-
Berlin, Germany
- Charité
-
Düsseldorf, Germany
- DaVita Clinical Research
-
Essen, Germany
- Uniklinikum
-
Mainz, Germany
- Hospital of Johannes Gutenberg University
-
-
-
-
-
Athens, Greece
- General Hospital of Athens
-
Heraklion, Greece
- General Hospital of Heraklion Venizeleio-Papaneio
-
Patras, Greece
- University General Hospital of Patras
-
Thessaloníki, Greece
- General Hospital of Thessaloniki
-
-
-
-
-
Chuncheon, Korea, Republic of
- Hallym University Sacred Heart Hospital
-
Jeju, Korea, Republic of
- Jeju National University Hospital
-
Seoul, Korea, Republic of
- Kyung Hee University Hospital at Gangdong
-
Seoul, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Konkuk University Hospital
-
-
-
-
-
Moscow, Russian Federation
- Botkin Hospital Moscow
-
Saint Petersburg, Russian Federation
- First Pavlov State Medical University of St. Petersburg
-
-
-
-
-
Kaohsiung, Taiwan
- Chang Gun Kaog Memorial Hospital
-
New Taipei City, Taiwan
- Shuang Ho Hospital
-
Taichung, Taiwan
- China Medical University Hospital
-
Taichung, Taiwan
- Taichung Veterans General Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
-
-
-
London, United Kingdom
- Kings College
-
Nottingham, United Kingdom
- Nottingham Renal and Transplant Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects > 18 to < 80 years (at date of signing the informed consent form [ICF]).
- Urine protein to creatinine ratio (UPCR) of > 3.0 g/g or proteinuria > 3.5 g/24 h
- Estimated glomerular filtration rate (eGFR) > 50 ml/min/1.73 m² (eGFR >30 and < 50 ml/min/1.73 m² can be included provided an interstitial fibrosis and tubular atrophy (IFTA) score of < 25% in a kidney biopsy)
- Not in spontaneous remission despite proper treatment with angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) (sufficient dose and treatment duration) as per clinical practice and scientific guidelines. If the subject is intolerant to ACEI and ARBs, the reason must be documented and approval for enrollment be obtained from the Medical Monitor.
- Systolic blood pressure (BP) <150 mmHg and diastolic BP <100 mmHg after 5 minutes of rest.
- Serum anti-PLA2R antibodies > 50.0 RU/mL determined by Euroimmun ELISA.
Female subjects: A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a female of childbearing potential (FCBP)
- A FCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of MOR202
Key Exclusion Criteria:
- Hemoglobin < 80 g/L.
- Thrombocytopenia: Platelets < 100.0 x 109/L.
- Neutropenia: Neutrophils < 1.5 x 109/L.
- Leukopenia: Leukocytes < 3.0 x 109/L.
- Hypogammaglobulinemia: Serum immunoglobulins ≤ 4.0 g/L.
Subjects may receive supportive therapies to meet the above criteria
- B-cells < 5 x 106/L
Diabetes mellitus type 2: Subjects with type 2 diabetes mellitus may only enter the clinical trial if a kidney biopsy performed within 6 months prior to screening shows MN without evidence of diabetic nephropathy and diabetes is controlled, as shown by:
- Glycated hemoglobin (HbAlc) <8.0 % or 64 mmol/mol.
- No diabetic retinopathy known.
- No peripheral neuropathy known.
- Total bilirubin, aspartate aminotransferase or alanine aminotransferase >1.5 x ULN, alkaline phosphatase >3.0 x ULN.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MOR202 Arm 1
5 doses administered on Day 1, 8, 15, 29, and 57
|
5 or 2 doses of MOR202 will be administered as an intravenous infusion
|
Experimental: MOR202 Arm 2
2 doses administered on Day 1 and 15
|
5 or 2 doses of MOR202 will be administered as an intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy: percent change of anti-PLA2R antibody levels
Time Frame: 3 months compared to baseline
|
efficacy of 2 different dosing regimens of MOR202 in subjects with anti-PLA2R antibody positive MN
|
3 months compared to baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy: immunological complete response (ICR) rate
Time Frame: ICR rate at 3 months, 6 months, 12 months and 24 months
|
efficacy of 2 different dosing regimens of MOR202
|
ICR rate at 3 months, 6 months, 12 months and 24 months
|
efficacy: overall proteinuria response (OPR) rate
Time Frame: OPR rate at 6 months, 12 months and 24 months.
|
efficacy of 2 different dosing regimens of MOR202
|
OPR rate at 6 months, 12 months and 24 months.
|
safety: determined by the frequency, incidence and severity of TEAEs
Time Frame: through treatment completion, an average of 3 months per treatment period
|
frequency, incidence and severity of treatment-emergent adverse events
|
through treatment completion, an average of 3 months per treatment period
|
PK profile
Time Frame: through study completion, an average of 1 year
|
MOR202 serum concentrations after multiple i.v.
administrations
|
through study completion, an average of 1 year
|
immunogenicity
Time Frame: through study completion, an average of 1 year
|
number of subjects developing anti-MOR202 antibodies
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: HI-Bio Clinical Program Lead, HI-Bio
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Nephritis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Glomerulonephritis
- Glomerulonephritis, Membranous
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Felzartamab
Other Study ID Numbers
- MOR202C205
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glomerulonephritis
-
Celldex TherapeuticsTerminatedC3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type IIUnited States
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedC3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and IIINetherlands, Australia, Belgium
-
Mario Negri Institute for Pharmacological ResearchAlexion PharmaceuticalsCompletedIC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative GlomerulonephritisItaly
-
University Magna GraeciaCompletedIGA GlomerulonephritisItaly
-
Apellis Pharmaceuticals, Inc.Active, not recruitingC3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
-
Apellis Pharmaceuticals, Inc.Active, not recruitingC3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
-
Apellis Pharmaceuticals, Inc.AvailableC3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...United States
-
Assiut UniversityUnknownMembranoproliferative Glomerulonephritis
-
Nagoya UniversityRohto Pharmaceutical Co., Ltd.Completed
-
AlexionTerminatedIC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative GlomerulonephritisUnited States, Australia, Belgium, Italy, Netherlands
Clinical Trials on MOR202
-
HI-BioCompletedTrial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (M-PLACE)Glomerulonephritis, Membranous | antiPLA2R PositiveSpain, Belgium, Australia, Italy, United States, Korea, Republic of, France, Netherlands, Poland
-
Mario Negri Institute for Pharmacological ResearchMorphoSys AGActive, not recruiting
-
HI-BioActive, not recruitingImmunoglobulin A (IgA) NephropathyUnited Kingdom, Germany, Spain, Serbia, Taiwan, Australia, Japan, Korea, Republic of, Belgium, United States, Bulgaria, Czechia, Georgia, Malaysia, Philippines, Ukraine
-
Farsad EskandaryCharite University, Berlin, Germany; University of Alberta; HI-BioCompleted